Open Menu Close Menu Open Search Close Search

Age-related Microbiota Changes and their Implications in Chronic Disease Prevention, Treatment and Progression (R21 Clinical Trial Optional)

The overall purpose of this funding opportunity announcement (FOA) is to assess the role of the microbiome in health and disease during aging. This initiative will support research projects designed to:

  • Evaluate changes in the microbiota during lifetime and its influence in health and disease status in the elderly, including those from racial/ethnic minority and underserved populations;
  • Understand the underlying mechanisms of microbiota interactions in aged subjects, in the context of multiple medications and chronic diseases;
  • Investigate how interventions designed to change the microbiota can reduce the risk and progression of age-associated pathologies, or modify the effect of treatment in aged animal models or humans.

This FOA utilizes the Exploratory/Developmental Grant (R21) mechanism, which supports investigation of novel scientific ideas or new model systems, tools, or technologies that have the potential for significant impact on biomedical or biobehavioral research.

Due Date: June 16

Age-related Microbiota Changes and their Implications in Chronic Disease Prevention, Treatment and Progression (R01 Clinical Trial Optional)

The overall purpose of this funding opportunity announcement (FOA) is to assess the role of the microbiome in health and disease during aging. This initiative will support research projects designed to:

  • Evaluate changes in the microbiota during lifetime and its influence in health and disease status in the elderly, including those from racial/ethnic minority and underserved populations;
  • Understand the underlying mechanisms of microbiota interactions in aged subjects, in the context of multiple medications and chronic diseases;
  • Investigate how interventions designed to change the microbiota can reduce the risk and progression of age-associated pathologies, or modify the effect of treatment in aged animal models or humans.

This FOA is intended for well-developed projects based on strong preliminary data. For exploratory pilot projects of similar scientific scope, prospective applicants are advised to consider the R21 companion FOA (PA-18-739).

Due Date: June 5